



## Corrigendum



## Corrigendum to “Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023–January 2024” [Vaccine 42 (19) (2024)]

Charlotte Laniece Delaunay<sup>a</sup>, Aryse Melo<sup>b</sup>, Marine Maurel<sup>a</sup>, Clara Mazagatos<sup>c</sup>, Luise Goerlitz<sup>d</sup>, Joan O’Donnell<sup>e</sup>, Beatrix Oroszi<sup>f</sup>, Noémie Sève<sup>g</sup>, Ana Paula Rodrigues<sup>h</sup>, Iván Martínez-Baz<sup>i</sup>, Adam Meijer<sup>j</sup>, Ivan Mlinarić<sup>k</sup>, Neus Latorre-Margalef<sup>l</sup>, Mihaela Lazăr<sup>m</sup>, Gloria Pérez-Gimeno<sup>c</sup>, Ralf Dürrwald<sup>n</sup>, Charlene Bennett<sup>o</sup>, Gergő Túri<sup>f</sup>, Marie-Anne Rameix-Welti<sup>p,q</sup>, Raquel Guiomar<sup>b</sup>, Jesús Castilla<sup>i</sup>, Mariëtte Hooiveld<sup>r</sup>, Sanja Kurečić Filipović<sup>k</sup>, Tove Samuelsson Hagey<sup>l</sup>, Frederika Dijkstra<sup>j</sup>, Vitor Borges<sup>s</sup>, Violeta Ramos Marín<sup>t</sup>, Sabrina Bacci<sup>u</sup>, Marlena Kaczmarek<sup>u</sup>, Esther Kissling<sup>a,\*</sup>, on behalf of the European primary care VE group

<sup>a</sup> Epiconcept, Paris, France

<sup>b</sup> National Reference Laboratory for Influenza Virus and Other Respiratory Viruses, Infectious disease department - National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

<sup>c</sup> National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain

<sup>d</sup> Robert Koch Institute, Berlin, Germany

<sup>e</sup> Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland

<sup>f</sup> National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary

<sup>g</sup> Sorbonne Université, INSERM, Institut Pierre Louis d’épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France

<sup>h</sup> Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

<sup>i</sup> Instituto de Salud Pública de Navarra - IdiSNA – CIBERESP, Pamplona, Spain

<sup>j</sup> National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands

<sup>k</sup> Croatian Institute of Public Health, Zagreb, Croatia

<sup>l</sup> Public Health Agency of Sweden, Stockholm, Sweden

<sup>m</sup> Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania

<sup>n</sup> National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany

<sup>o</sup> UCD-National Virus Reference Laboratory University College Dublin, Dublin, Ireland

<sup>p</sup> Centre National de Référence Virus des Infections Respiratoires (CNR VIR) Institut Pasteur Université Paris Cité, Paris, France

<sup>q</sup> Institut Pasteur, Université Paris-Saclay, Université de Versailles St. Quentin, Université Paris Cité, UMR 1173 (2I), INSERM; Assistance Publique des Hôpitaux de Paris, Paris, France

<sup>r</sup> Nivel, Utrecht, the Netherlands

<sup>s</sup> Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

<sup>t</sup> Servicio de Epidemiología de la Consejería de Sanidad y Servicios Sociales de Ceuta, Ceuta, Spain

<sup>u</sup> European Centre for Disease Prevention and Control, Stockholm, Sweden

The authors regret that there was an error in two dates in Table 1, which includes autumn 2023 national COVID-19 vaccination campaign dates by study site. We update here the date for Germany, which was 18 September 2023, and for Navarre, Spain, which was 16 October, 2023. These dates were used in the analysis, so the error in Table 1 does not

affect results or findings. The corrected Table 1 is as follows:

Table 1. Autumn 2023 national COVID-19 vaccination campaign, vaccination and recruitment information, by study site, VEBIS primary care study, September 2023–January 2024

DOI of original article: <https://doi.org/10.1016/j.vaccine.2024.05.067>.

\* Corresponding author.

E-mail address: [e.kissling@epiconcept.fr](mailto:e.kissling@epiconcept.fr) (E. Kissling).

<https://doi.org/10.1016/j.vaccine.2024.06.056>

Available online 8 July 2024

0264-410X/© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Study sites included in the analysis	Start of autumn 2023 national COVID-19 vaccination campaigns	Age-specific recommendation for COVID-19 vaccination for older adults	Data source for COVID-19 vaccination information	Case definition used for recruitment of patients <sup>b</sup>
Croatia	18 Sep 2023	65	Medical records, vaccination registry, GP interview (self-report)	EU-ILI or EU-ARI
France	2 Oct 2023	65	GP interview (self-report)	Sentinelles ARI
Germany	18 Sep 2023	60	Medical records, patient's certificate of vaccination, GP interview (self-report)	ARI
Hungary	1 Oct 2023	60	National Immunisation Registry (83.5%), GP records, self-report	EU-ARI
Ireland	2 Oct 2023	50	Data linkage to vaccine registry	EU-ARI
The Netherlands	2 Oct 2023	60	GP interview (self-report)	EU-ILI or EU-ARI
Portugal	29 Sep 2023	60	Vaccine registry look-up by GPs	EU-ARI
Spain, national	25 Sep 2023	60	Data linkage to vaccine registry	EU-ARI
Spain, Navarre region <sup>c</sup>	16 Oct 2023	60	Data linkage to vaccine registry	EU-ILI
Sweden	7 Nov 2023	65	Data linkage to vaccine registry	EU-ARI

ARI: acute respiratory infection; EU: European Union; ILI: influenza-like illness; VEBIS: Vaccine Effectiveness, Burden and Impact Studies.

<sup>a</sup> Romania was excluded from the analysis due to too small a sample size (<10 cases).

<sup>b</sup> EU-ARI: Sudden onset of symptoms and at least one of four respiratory symptoms (cough, sore throat, shortness of breath, coryza) and a clinician's judgement that the illness is due to an infection; EU-ILI: Sudden onset of symptoms and at least one of four systemic symptoms

(fever or feverishness, malaise, headache, or myalgia) and at least one of three respiratory symptoms (cough, sore throat, or shortness of breath); Sentinelles ARI: Sudden onset of fever (or feverishness), and respiratory signs; The ARI case definition in Germany includes patients with at least one of the following four symptoms: fever, cough, coryza or sore throat.

<sup>c</sup> Some vaccination may have taken place from 25 September 2023.

The authors would like to apologise for this oversight and for any inconvenience caused.